Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inovio Pharma (INO)

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Inovio Welcomes Biotech Leader to its Board of Directors

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and financial experience to the board given his tenure...

INO : 3.29 (-3.24%)
BLS Pharma Alleges Inovio's Breach of Contract Obstructed Ability to Deliver Testosterone Replacement Therapy for Hypogonadism and the Transgender Community

BLS Pharma, Inc. filed a complaint late last month against Genetronics, Inc. and Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Case No. 30-2019-01119045, for breaching a contract to supply a needle-free...

INO : 3.29 (-3.24%)
Inovio Provides Update on Clinical Program Plans for 2020

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical program goals for 2020 at the Biotech Showcase...

INO : 3.29 (-3.24%)
Look for Shares of Inovio Pharmaceu to Potentially Rebound after Yesterday's 1.18% Sell Off

Inovio Pharmaceu (NASDAQ:INO) traded in a range yesterday that spanned from a low of $3.34 to a high of $3.43. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $3.36...

INO : 3.29 (-3.24%)
Inovio Pharmaceu Rises 3.33% on Heavy Volume: Watch For Potential Pullback

Inovio Pharmaceu (NASDAQ:INO) traded in a range yesterday that spanned from a low of $3.23 to a high of $3.46. Yesterday, the shares gained 3.3%, which took the trading range above the 3-day high of...

INO : 3.29 (-3.24%)
Merck's Ebola Vaccine Ervebo Gets Approval in United States

FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.

GSK : 47.89 (+1.55%)
MRK : 90.99 (-0.21%)
INO : 3.29 (-3.24%)
REGN : 385.94 (+0.10%)
Look for Shares of Inovio Pharmaceu to Potentially Rebound after Yesterday's 1.90% Sell Off

Inovio Pharmaceu (NASDAQ:INO) traded in a range yesterday that spanned from a low of $2.56 to a high of $2.66. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $2.61...

INO : 3.29 (-3.24%)
Inovio (INO) Up 14.3% Since Last Earnings Report: Can It Continue?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 3.29 (-3.24%)
Vaccines Market to Reach USD 93.08 billion by 2026, Approval For DENGVAXIA by USFDA to Spur Sales Opportunities, says Fortune Business Insights

The global Vaccines Market size is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during the forecast period. The growing prevalence of malaria around the world is a key factor boosting...

CSLLY : 73.0800 (-30.07%)
INO : 3.29 (-3.24%)
MRK : 90.99 (-0.21%)
NVS : 95.93 (+0.87%)
PFE : 40.45 (-0.39%)
Inovio Pharmaceu Rises 2.44% on Heavy Volume: Watch For Potential Pullback

Inovio Pharmaceu (NASDAQ:INO) traded in a range yesterday that spanned from a low of $2.43 to a high of $2.57. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of...

INO : 3.29 (-3.24%)
SmarTrend Watching for Potential Pullback in Shares of Inovio Pharmaceu After 1.73% Gain

Inovio Pharmaceu (NASDAQ:INO) traded in a range yesterday that spanned from a low of $2.58 to a high of $2.70. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of...

INO : 3.29 (-3.24%)
Inovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday,...

INO : 3.29 (-3.24%)
Inovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November...

INO : 3.29 (-3.24%)
Inovio's (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus

Inovio's (INO) loss in the third quarter meets estimates while revenues miss the same. Lead vaccine candidate VGX-3100 is in focus.

AZN : 51.33 (+1.62%)
SNY : 51.24 (+0.10%)
REGN : 385.94 (+0.10%)
INO : 3.29 (-3.24%)
Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates

Inovio (INO) delivered earnings and revenue surprises of 0.00% and -68.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

INO : 3.29 (-3.24%)
Inovio: 3Q Earnings Snapshot

PLYMOUTH MEETING, Pa. (AP) _ Inovio Pharmaceuticals Inc. (INO) on Tuesday reported a loss of $23.1 million in its third quarter.

INO : 3.29 (-3.24%)
Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious...

INO : 3.29 (-3.24%)
Merck's Ebola Vaccine Gets Conditional Approval in Europe

European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.

MRK : 90.99 (-0.21%)
GSK : 47.89 (+1.55%)
REGN : 385.94 (+0.10%)
INO : 3.29 (-3.24%)
Patients Turn to Advanced Technology in Order to Combat Cancer

Over the past two decades, cancer-related deaths in the U.S. have declined significantly. As of 2015, the death rate for both men and women declined by 26% from its peak in 1991, according to the American...

ONPH : 0.0190 (+10.47%)
INO : 3.29 (-3.24%)
REGN : 385.94 (+0.10%)
AVEO : 0.64 (-3.12%)
SLS : 3.07 (+1.32%)
NWBO : 0.2100 (+1.94%)
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INO : 3.29 (-3.24%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar